Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

President Michael Maves, MD, officially took the helm of the trade association Oct. 1, replacing James Cope, who retired after 38 years with CHPA. Maves most recently served as exec VP of the American Academy of Otolaryngology - Head and Neck Surgery, based in Alexandria, Va. His appointment as president unanimously cleared the CHPA board of directors May 21 (1"The Tan Sheet" May 24, p. 3)

You may also be interested in...

CHPA's New President Is ENT Surgeon, Academy Exec Michael Maves

The Consumer Healthcare Products Association went outside the industry but stayed within D.C. and the medical area to find its next president, Michael Maves, MD.

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts